Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-08
  • MK-571 sodium salt hydrate br Disclosure br DAY has the foll

    2019-11-05


    Disclosure
    DAY has the following disclosures: Institutional Consulting/Advisory Role (Novartis, Genentech/Roche, Daiichi Sankyo/Lilly, Eisai, Celgene, Biotheranostics, NanoString Technologies, Bristol-Myers Squibb); Personal Speakers' Bureau (Novartis, Genentech/Roche); Institutional Research Funding (AstraZeneca, Genentech/Roche, Syndax, Novartis, MedImmune, Lilly, Medivation, Pfizer, Eisai, Tesaro, Macrogenics, Abbvie, Immunomedics, Daiichi Sankyo, Merck, Clovis Oncology, Oncothyreon, InventisBio); Personal Travel, Accommodations, Expenses (Novartis, Genentech/Roche). JDH has the following disclosures: Institutional Funding (Roche/Genentech, Novartis, Takeda, Astellos). HAB has the following disclosures: Institutional Consultant/Advisory Role (Mersana, AstraZeneca, FORMA Therapeutics, Janssen, Novartis, Roche/Genentech, TG Therapeutics, MedImmune, Bristol-Myers Squibb), Institutional Funding (Roche/Genentech, Bristol-Myers Squibb, Incyte, Tarveda Therapeutics, Mersana, AstraZeneca, MedImmune, Macrogenics, Novartis, Boehringer Ingelheim, Lilly, Seattle Genetics, Abbvie, Bayer, Celldex, Merck, Celgene, Agios, Jounce Therapeutics, Moderna Therapeutics, CytomX Therapeutics, GlaxoSmithKline, Verastem, Tesaro, Immunocore, Takeda, Millennium, BioMed Valley Discoveries, Pfizer, PTC Therapeutics, TG Therapeutics, Loxo, Vertex, eFFECTOR Therapeutics, Janssen, Gilead Sciences, Valent Technologies, BioAtla, CicloMed, Harpoon Therapeutics, Jiangsu Hengrui Medicine, Revolution Medicines, Daiichi Sankyo, H3 Biomedicine, Neon Therapeutics, OncoMed, Regeneron, Sanofi), Personal Expert Testimony (Novartis). All other authors have no conflicts of interest to declare.
    ACCEPTED MANUSCRIPT
    REFERENCES
    1. Campbell RA, Bhat-Nakshatri P, Patel NM, et al. Phosphatidylinositol 3-kinase/AKT mediated activation of MK-571 sodium salt hydrate receptor alpha: a new model for antiestrogen resistance. J Biol Chem 2001; 276:9817-9824.
    2. Santen RJ, Song RX, Zhang Z, et al. Adaptive hypersensitivity to estrogen mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment. J Steroid Biochem Mol Biol 2005; 95:155-65.
    3. Tokunaga E, Kimura Y, Oki E, et al. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 2006; 118:284-89.
    5. Conciatori F, Ciuffreda L, Bazzichetto C, Falcone I, Pilotto S, Bria E , Cognetti, Milella M. mTOR Cross-Talk in Cancer and Potential for Combination Therapy. Cancers 2018; 10:23.
    6. Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O’Reilly T, Evans DB, Chen S, Lane HA. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005; 11:5319–5328.
    7. Bachelot T, Bourgier C, Cropet C et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO Study. Clin Oncol 2012; 30:2718- 24.
    8. Baselga J, Campone M, Piccart M, Burris HA 3rd,et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Eng J Med 2012; 366:520-29.
    9. Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with HR+ breast cancer: BOLERO-2 final progression-free Survival Analysis. Adv Ther 2013; 30:870-84.
    10. Carbone DP, Ding K, Roder H, et al. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial. J Thorac Oncol 2012; 7:1653-60.
    12. Cardoso F, Villanueva C, Royce M, Cruz F, Debled M, Hegg R, et al. Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC): First- and second-line data from the BOLERO-4 study. J Clin Oncol 2017; 35: 1010.